**Appendix Table D66. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Masking****of Treatment** | **Planned Intention to Treat Analysis** | **Allocation Concealment** | **Adequacy of Randomization** | **Selective Outcome Reporting** | **Risk of Bias** | **Other Concerns** |
| Millan-Guerrero, 2009160 | Double blind | No | Unclear | Yes | Unclear | Low | Poor reporting quality |
| Mathew, 2009161 | Double blind | No | Unclear | No | Unclear | Medium |  |
| Magalhaes, 2010162 | Open label | No | Unclear | Unclear (age seems to differ by groups; no tests conducted) | Unclear | High |  |
| Cady, 2011163 | Double blind | No | Unclear | Unclear (unclear in demographic characters, but adequate in migraine characteristics) | Unclear | Medium |  |
| Blumenfeld, 2008164 | Double blind | Yes | Unclear | No | Unclear | Medium | Baseline Headache severity differs by groups |